Japan Grants Orphan Drug Status to Quoin Pharma's QRX003, Offering Key Incentives
QNRX is trading near its 52-week low of $4.11 (15% above the low) on light trading volume (0.3× avg).
Summary
Quoin Pharmaceuticals secured Orphan Drug Designation from Japan's MHLW for its lead candidate, QRX003, for Netherton Syndrome. This follows an 8-K filing earlier today and adds to prior FDA and EMA orphan designations. The designation provides significant regulatory incentives, including market exclusivity for up to 10 years in Japan, which is a material de-risking event for the drug's development and commercialization. For this micro-cap biotech, this is a crucial step towards global market access for its lead asset. The company anticipates starting a pivotal Phase 3 trial in the second half of 2026.
At the time of this announcement, QNRX was trading at $4.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $4.11 to $41.80. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.